Both in Pharmaceuticals
UroGen Pharma vs Pacira BioSciences
Over the past year URGN returned +45.1% and PCRX returned +62.2%; their daily moves had a correlation of -0.09.
URGN +45.1% PCRX +62.2%Growth of $1, one year, split-adjusted
| Metric | URGN | PCRX |
|---|---|---|
| Price | $28.74 | $36.40 |
| Market cap | $1.40B | $1.45B |
| Today | −16.45% | +0.03% |
| 1 month | −30.6% | +47.0% |
| 6 months | +9.5% | +53.7% |
| Year to date | +22.7% | +40.6% |
| 1 year | +39.4% | +64.0% |
| Revenue growth (YoY) | +199.2% | +6.2% |
| Gross margin | 90.9% | 77.0% |
| Net margin | −19.8% | 2.4% |
| P/E (TTM) | — | 99.2× |
| Price / sales | 7.4× | 1.9× |
| Net cash | -$85.1M | -$112.1M |
| Dividend yield | — | — |
| Volatility (60d) | 54.9% | 78.5% |
| Short % of float | 12.3% | 11.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).